Takeda says multiyear restructuring is ‘on track’news2024-10-31T15:21:41+00:00October 31st, 2024|Endpoints News|
Amgen makes pipeline cuts, but obesity plans remain the focusnews2024-10-31T11:03:08+00:00October 31st, 2024|Endpoints News|
Corcept misses primary endpoint in supportive Cushing’s syndrome studynews2024-10-31T10:37:53+00:00October 31st, 2024|Endpoints News|
Compass Pathways delays key Phase 3 psilocybin readouts, spurring 30% layoffsnews2024-10-31T10:30:08+00:00October 31st, 2024|Endpoints News|
Lexeo shares early data on Alzheimer’s gene therapy news2024-10-30T19:29:49+00:00October 30th, 2024|Endpoints News|
Roche presents early-stage results for latest amyloid-based Alzheimer’s attemptnews2024-10-30T18:51:34+00:00October 30th, 2024|Endpoints News|
Atlas of tumors reveals in 3D how cells change into cancernews2024-10-30T17:47:06+00:00October 30th, 2024|Endpoints News|
Biogen seeks growth from pipeline as investors show signs of impatiencenews2024-10-30T17:11:27+00:00October 30th, 2024|Endpoints News|
GSK cuts 24-valent pneumococcal program for adults due to competitionnews2024-10-30T14:39:58+00:00October 30th, 2024|Endpoints News|
Zurzuvae won’t be developed for major depression, Sage saysnews2024-10-29T21:33:24+00:00October 29th, 2024|Endpoints News|
